Aqueous Humor Oxidative Stress Markers in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2007 - March 31, 2010
Grant ID
G2007022
Goals
Our proposed study will examine the aqueous humor, the fluid in the front of the eye, of patients who are undergoing eye surgery. We will measure both a byproduct (hydrogen peroxide) and a protectant (ascorbic acid) of oxidative damage, as well as oxygen levels in different parts of the front of the eye. By aiding in further understanding of this oxidative mechanism of glaucoma damage, it may lead to innovative therapies for this devastating condition.
Summary
Glaucoma, the second leading cause of blindness worldwide, is characterized by damage to the optic nerve which transmits visual information from the eye to the brain. Most cases are associated with increased eye pressure and decreased outflow through the drainage meshwork in the front of the eye. Current theories suggest that this age-related disease, as well as other eye conditions like cataract and macular degeneration, may be related to oxidative damage, toxic effects of excess oxygen forming harmful molecules called free radicals.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester